Evommune, Inc. (EVMN) SEC Filings & Earnings Calls

Clinical-stage biotech with no approved products; reliance on EVO301 and pipeline success.

“clinical-stage biotechnology company developing innovative therapies” · word for word

Clinical development risk; Phase 2a data not yet disclosed; Phase 2b not yet started.

“The Phase 2b dose-ranging study for EVO301 in moderate-to-severe AD, anticipated to begin in mid-2027” · word for word

Clinical-stage biotech with no approved products; pipeline execution risk.

“Forward-looking statements about clinical trials and regulatory approvals.”

Competitive landscape in chronic inflammation with established therapies.

“Treatments Have Critical Limitations… but many competitors exist.”

Clinical trial failure for lead asset EVO756 in atopic dermatitis; pipeline setback.

“trial did not meet the primary and secondary endpoints in any of the doses studied” · word for word

Clinical trial risk: EVO756 CSU trial failed; AD and migraine trials still pending.

“The study did not meet the primary endpoint... Evommune has discontinued development of EVO756 in CSU” · word for word

No revenue; net loss widening; reliance on pipeline success.

“Net loss totaled $32.2 million... compared to $13.6 million”

Clinical trial failure

“The trial did not meet its primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose, and based on these results, we have decided to cease development of EVO756 for CSU.” · word for word

Cash burn and need for additional funding

“We expect to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenue to support its cost structure.”

Dependence on pipeline success

“We are heavily dependent on the success of our product candidates, EVO756 and EVO301, which are still in clinical development.”

Clinical trial risk: Phase 2b trial may fail to meet endpoints.

“Top-line data expected in 2027; no efficacy data yet.”

Clinical trial failure for lead candidate EVO756 in CSU

“Phase 2b trial did not meet primary endpoint; development for CSU ceased.”

Clinical trial failure risk

“We have incurred significant operating losses in each year since our inception. As of March 31, 2026, we had an accumulated deficit of $242.8 million.” · word for word

Dependence on future funding

“We will require substantial additional funding to further develop our product candidates and support our continuing operations.” · word for word

Clinical trial failure risk for EVO756 and EVO301; no approved products.

“All pipeline assets are in clinical development; no commercial revenue.”

Revenue decline to zero from prior collaboration revenue.

“Revenue $0 vs $3.0M YoY due to Maruho collaboration timing.”

Early-stage biotech with no approved products or revenue disclosed

“No revenue or product approval mentioned in the proxy; the company is a clinical-stage biopharmaceutical company.”

Key person dependency on CEO and CMO who are also directors

“Luis Peña and Eugene A. Bauer serve as both executive officers and directors, creating potential governance concentration.” · word for word

Pre-revenue biotech with significant net losses and reliance on pipeline success.

“Net loss $68.9M for FY2025; no product revenue.”

Clinical trial risks for EVO756 and EVO301; data readouts may fail.

“EVO756 Phase 2b data expected in 2026; EVO301 Phase 2b planning underway.”

Clinical trial failure risk

“Preclinical and clinical drug development is a lengthy and expensive process, with uncertain timelines and outcomes. If preclinical studies or clinical trials of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals.” · word for word

Capital requirement risk

“We will need substantial additional funding in order to maintain our operations and advance the development and commercialization of our product candidates, if approved. Failure to obtain this necessary capital when needed, or on acceptable terms, may force us to delay, reduce or eliminate certain of our research operations or development.” · word for word

Safety risk

“Our product candidates may be associated with serious adverse, undesirable or unacceptable side effects or other properties or safety risks, which may delay or halt their clinical development, prevent their marketing approval, or lead to limited market demand, if approved.” · word for word

Competition risk

“We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.” · word for word

Regulatory approval risk

“Our product candidates are subject to extensive regulatory and compliance obligations, which is costly and time-consuming and which may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.” · word for word

Going concern risk alleviated but still early stage

“management implemented plans that alleviated the substantial doubt” · word for word

Dependence on milestone and license revenue

“License revenue $10,000 for three months ended September 30, 2025 compared to $0 for the same period in 2024”

Clinical-stage company with no approved products; pipeline risk.

“Three Phase 2 readouts expected in 2026; no guarantee of success.”

Dependence on IPO proceeds and cash runway; burn rate may require future financing.

“Net loss $12.5M in Q3 2025; cash $76M; IPO raised $172.5M but ongoing R&D spend.”